BEL116472. A 2 Year Mechanistic Study of Belimumab in Idiopathic Membranous Glomerulonephropathy

Trial Profile

BEL116472. A 2 Year Mechanistic Study of Belimumab in Idiopathic Membranous Glomerulonephropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Belimumab (Primary)
  • Indications Membranous glomerulonephritis
  • Focus Biomarker; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 04 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top